Allos is pursuing regulatory authorization to market FOLOTYN in europe for refractory or relapsed PTCL. Allos’ Marketing Authorisation Software was approved for review by the European Medications Company in December 2010. Under the collaboration, Allos will receive an upfront payment of $50 million and potential regulatory and commercial improvement – and sales-dependent milestone payments of up to $310.5 million. Allos is also entitled to receive tiered double-digit royalties predicated on net sales of FOLOTYN within Mundipharma’s licensed territories.The reduction in severe exacerbations was also significant: in a post hoc calculation, the quantity needed to treat in order to prevent one serious exacerbation through the 48-week treatment period was 15. The gains observed in trials 1 and 2, though relatively small, should be seen in the context of the necessity for additional treatments for this patient population and the restrictions of current alternatives. Leukotriene-receptor theophylline and antagonists have shown little, if any, benefit in this patient people; oral glucocorticoids are connected with severe side effects; and other treatments, such as for example omalizumab, are suitable limited to a subgroup of sufferers.